 |
27 Diseases |  |
27 Trials |
|
27 Trials |  |
307 News |  |
| 12345678» |
- | Eylea (aflibercept intravitreal) / Regeneron, Lumitin (conbercept) / Chengdu Kanghong Pharma
Retrospective data, Journal: Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity. (Pubmed Central) - Jan 28, 2025
CRAE was associated with not only the severity of ROP but also its reactivation. Additionally, it may be an objective indicator in the early indication and follow-up of ROP.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: A Novel Bispecific Anti-IL17/VEGF Fusion Trap Exhibits Potent and Long-Lasting Inhibitory Effects on the Development of Age-Related Macular Degeneration. (Pubmed Central) - Dec 30, 2024
More importantly, 17V05 also exhibited stronger and longer inhibitory effects than conbercept in vivo. Thus, we provide a novel and promising strategy for treating AMD patients who are not sensitive to anti-VEGF therapies.
- | Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Short-term fluctuation of intraocular pressure and influencing factors following intravitreal injection in patients with retinal vascular diseases. (Pubmed Central) - Nov 19, 2024
Needle size plays a crucial role in the transient changes of IOP following intravitreal injection. Before administering intravitreal injection to patients with central retinal vein occlusion, it is essential to exclude any underlysing causes of increased IOP.
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: The analysis of foveal microvascular anomalies in retinopathy of prematurity after anti-vascular endothelial growth factor therapy using optical coherence tomography angiography. (Pubmed Central) - Nov 19, 2024
ROP children have a thicker CFT than healthy children, except for those treated with Conbercept. Furthermore, microvascular irregularities were correlated with central foveal thickness.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New P4 trial: Comparison of subretinal versus intravitreal injection of tissue type plasminogen activator combined with conbercept and C3F8 in the treatment of acute macular hemorrhage (EUDRACT) - Nov 10, 2024
P4, N=40, Recruiting, Sponsor: Dongguan Guangming Ophthalmology Hospital; Dongguan Guangming Ophthalmology Hospital
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: INTRAVITREAL INJECTION CONBERCEPT IMPROVES THE BEST-CORRECTED VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR EDEMA. (Pubmed Central) - Oct 23, 2024
Furthermore, microvascular irregularities were correlated with central foveal thickness. The BCVA values of the effective group were lower than those of the ineffective group, and the BCVA changes of the effective group before and after treatment were greater than those of the ineffective group, suggesting that conbercept can improve the visual acuity of patients with macular edema caused by wet age-related macular degeneration.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Vascular endothelial growth factor/connective tissue growth factor and proteomic analysis of aqueous humor after intravitreal conbercept for proliferative diabetes retinopathy. (Pubmed Central) - Oct 21, 2024
The study demonstrates that IVC effectively reduces VEGF levels while increasing CTGF levels, thereby modifying the CTGF/VEGF ratio, and IVC significantly alters the protein profile in the aqueous humor of patients with PDR. Proteomic analysis reveals that these changes are associated with critical biological pathways and protein interactions involved in immune response, stress response, and cellular metabolism.
- || mitomycin / Generic mfg.
Review, Journal, Surgery: The efficacy of adjunctive mitomycin C and/or anti-VEGF agents on glaucoma tube shunt drainage device surgeries: a systematic review. (Pubmed Central) - Oct 7, 2024
There is no high-quality evidence to support the use of MMC in tube shunt surgery. As for anti-VEGF agents, specifically bevacizumab, significant benefit seems to exist in neovascular glaucoma patients, especially if combined with PRP.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Evaluating the Efficacy of Conbercept and Dexamethasone Implants Sequentially in the Treatment of Refractory Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO): A One-Year Follow-Up Study. (Pubmed Central) - Oct 7, 2024
In conclusion, patients experiencing persistent ME due to secondary CRVO may benefit from transitioning to a treatment regimen involving Conbercept and DEX I, potentially resulting in a reduction in CRT. However, no significant improvement was observed in BCVA or deep and superficial capillary plexus vessel density.
- RC28-E / Rongchang Pharma
Simultaneous Inhibition of Fibroblast Growth Factor-2 and VEGF-A With RC28-E in DME: A Phase 2 Randomized Trial (DEMAND) - Sep 24, 2024 - Abstract #AAO2024AAO_2395;
Incidence of ocular and non-ocular adverse events was comparable between RC28-E groups and the conbercept group. Conclusion RC28-E demonstrated efficacy and tolerability comparable with those of conbercept in DME.
- | Eylea (aflibercept intravitreal) / Regeneron, Lumitin (conbercept) / Chengdu Kanghong Pharma
New P4 trial: Comparison of the Efficacy of Conbercept and Aflibercept in Different Treatment Regimens for Exudative Age-related Macular Degeneration (EUDRACT) - Sep 20, 2024
P4, N=140, Completed, Sponsor: The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Biomarker, Journal: Multimodal imaging diagnosis and analysis of prognostic factors in patients with adult-onset Coats disease. (Pubmed Central) - Aug 19, 2024
Anti-VEGF treatment combined with laser therapy can be an option for improving or maintaining BCVA and resolving macular edema. The final visual outcome depends on macular involvement and the disease stage.
- || Clinical, Retrospective data: Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis. (Pubmed Central) - Jul 30, 2024
The aim of this study was to compare the efficacy of intravitreal aflibercept (IVA), intravitreal bevacizumab (IVB), intravitreal conbercept (IVC), intravitreal ranibizumab (IVR), and laser therapy in treating these conditions...Our analysis concludes that intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drug monotherapy generally offer better outcomes than laser treatment for ROP. Nonetheless, additional RCTs are necessary to further evaluate the safety of anti-VEGF agents.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Retrospective data, Journal: Clinical and genetic features in autosomal recessive bestrophinopathy in Chinese cohort. (Pubmed Central) - Jul 26, 2024
This study provides a comprehensive characterization of anterior segment and genetic features in ARB, with a wide array of morphological abnormalities. Findings are relevant for refining clinical practices and genetic counseling and advancing pathogenesis research.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New trial: Effect of conbercept on the microRNAs of proliferative diabetic retinopathy (EUDRACT) - Jul 15, 2024
P=N/A, N=30, Not yet recruiting, Sponsor: Wuhan Aier Eye Hanyang Hospital; Wuhan Aier Eye Hanyang Hospital
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New trial: Observation of macular blood flow density and changes of cytokines in anterior chamber water after treatment of diabetes macular edema with Conbercept combined with dexamethasone vitreous implant (EUDRACT) - Jul 15, 2024
P=N/A, N=60, Not yet recruiting, Sponsor: Inner Mongolia Chaoju Eye Hospital; Inner Mongolia Chaoju Eye Hospital
- || Lumitin (conbercept) / Chengdu Kanghong Pharma
Clinical, Journal: Intravitreal Injection of Conbercept Combined with Dexamethasone for Macular Edema Following Central Retinal Vein Occlusion. (Pubmed Central) - Jul 1, 2024
The study was registered with the Chinese Clinical Trial Registry at 5 July 2017. (http://www.chictr.org.cn, 05/07/2017 Registration Number: ChiCTR-INR-17011877).
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Biomarker, Retrospective data, Journal: Prognostic factors for intravitreal conbercept in the treatment of choroidal neovascularization secondary to pathological myopia. (Pubmed Central) - Jun 22, 2024
Conbercept demonstrates significant efficacy and safety in treating PM-CNV. Key factors influencing visual recovery post-treatment include older age, poorer baseline BCVA, the presence of subfoveal CNV, and organized interlacing patterns of CNV morphology.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
Clinical, Retrospective data, Review: Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-related Macular Degeneration: An Updated Meta-analysis. (Pubmed Central) - Jun 20, 2024
Key factors influencing visual recovery post-treatment include older age, poorer baseline BCVA, the presence of subfoveal CNV, and organized interlacing patterns of CNV morphology. In patients with AMD, the CFH Y402H is a predictor of the response to anti-VEGF agents and should be considered in the treatment plan.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Intravitreal conbercept injection with panretinal photocoagulation for high-risk proliferative diabetic retinopathy with vitreous hemorrhage. (Pubmed Central) - Jun 19, 2024
In patients with AMD, the CFH Y402H is a predictor of the response to anti-VEGF agents and should be considered in the treatment plan. The study suggests that the combination of PRP with IVC injections is an effective and safe modality for treating diabetic VH in patients with HR-PDR.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
Retrospective data, Review, Journal: Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis. (Pubmed Central) - Jun 9, 2024
In the SUCRA plots, LPC had a markedly different position with a higher probability for myopia. Further clinical trials comparing different intravitreal doses of anti-VEGF agents are needed, but our findings suggest that low doses of these drugs retain efficacy and may reduce ocular and systemic undesired events.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
Clinical, Retrospective data, Review, Journal: Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography: A network meta-analysis. (Pubmed Central) - Jun 7, 2024
And, conbercept exhibited the highest reduction in CMT in the DRT, CME, and SRD groups. In conclusion, our study highlights the efficacy of anti-VEGF agents in the management of DME and provides valuable insights into the selection of anti-VEGF agents tailored to the individual needs of patients.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lumitin (conbercept) / Chengdu Kanghong Pharma
Clinical, Journal: Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration. (Pubmed Central) - May 26, 2024
P2/3
Both Conbercept and Aflibercept are clinically similar in efficacy for nAMD, with the T&E regimen proving therapeutically effective and potentially reducing patient costs. Anti-VEGF treatment efficacy varies across nAMD subtypes, indicating a potential benefit in tailored treatments for specific subtypes.Clinical trial registration number NCT05539235 (Protocol Registration and Results System).
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Differences between young and elderly polypoidal choroidal vasculopathy patients with and without pachychoroid phenotypes. (Pubmed Central) - May 20, 2024
Anti-VEGF treatment efficacy varies across nAMD subtypes, indicating a potential benefit in tailored treatments for specific subtypes.Clinical trial registration number NCT05539235 (Protocol Registration and Results System). PCV patients stratified by subtype exhibit distinct characteristics between the young and elderly groups.
- || Retrospective data, Review, Journal: Treatment of myopic choroidal neovascularization: a network meta-analysis and review. (Pubmed Central) - May 20, 2024
PCV patients stratified by subtype exhibit distinct characteristics between the young and elderly groups. This network meta-analysis confirms that anti-VEGF is the most effective treatment for myopic CNV using the 1?+?PRN treatment strategy.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Safety and efficacy of intravitreal injection of conbercept for the treatment of patients with choroidal neovascularization secondary to pathological myopia: Results from the SHINY study. (Pubmed Central) - Apr 26, 2024
This network meta-analysis confirms that anti-VEGF is the most effective treatment for myopic CNV using the 1?+?PRN treatment strategy. Intravitreal injections of 0.5?mg conbercept provided improvement in visual and anatomical outcomes in pmCNV patients with low rates of ocular and nonocular safety events.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Clinical efficacy of conbercept injection on neovascular age-related macular degeneration under different levels of inflammation. (Pubmed Central) - Apr 26, 2024
Furthermore, conbercept is associated with the reduction of inflammatory factor (IL-6 and IL-8) levels after intravitreal injection, which suggests that suppressing inflammatory response might contribute to the clinical efficacy of anti-VEGF treatment. Our results provide a novel mechanism for conbercept in patients with neovascular AMD.
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Comparative quantitative analysis of optical coherence tomography angiography in varied morphologies of macular neovascularization following intravitreal conbercept and ranibizumab treatments for neovascular age?related macular degeneration. (Pubmed Central) - Apr 9, 2024
On the other hand, ranibizumab might be considered an effective intervention for individuals with seafan MNV patterns. Notably, the Medusa MNV pattern was associated with a morphologic configuration indicative of a poor prognosis.
- || Ozurdex (dexamethasone intravitreal implant) / AbbVie
Clinical: The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy. (Pubmed Central) - Mar 13, 2024
Ozurdex may help to improve the visual acuity and visual sensitivity, and there is no significant difference in the change of IOP and microvascular improvement. This trial is registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn, registration number ChiCTR2100043399).
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New P4 trial: Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy (clinicaltrials.gov) - Mar 12, 2024
P4, N=58, Recruiting, Sponsor: Shanghai Eye Disease Prevention and Treatment Center
- Vabysmo (faricimab-svoa) / Roche
Comparative Effectiveness of Faricimab and Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema in China: A Network Meta-Analysis () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2232;
This trial is registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn, registration number ChiCTR2100043399). This NMA showed intravitreal faricimab regimens resulted in statistically beneficial effects on BCVA improvement and CMT reduction, also had the highest probability of being the most effective options in VFQ-25 scores, number of injections and a higher proportion of patients with a gain of at least 15 ETDRS letters compared to ranibizumab, conbercept, aflibercept or laser group after one-year treatment in China.
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Clinical evaluation of ranibizumab and conbercept for the treatment of macular oedema secondary to central retinal vein occlusion. (Pubmed Central) - Mar 6, 2024
This NMA showed intravitreal faricimab regimens resulted in statistically beneficial effects on BCVA improvement and CMT reduction, also had the highest probability of being the most effective options in VFQ-25 scores, number of injections and a higher proportion of patients with a gain of at least 15 ETDRS letters compared to ranibizumab, conbercept, aflibercept or laser group after one-year treatment in China. No abstract available
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Enrollment open, Trial completion date, Trial primary completion date: Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-na (clinicaltrials.gov) - Mar 6, 2024
P=N/A, N=102, Recruiting, Sponsor: Tianjin Medical University Eye Hospital
No abstract available Not yet recruiting --> Recruiting | Trial completion date: Nov 2025 --> Sep 2026 | Trial primary completion date: Nov 2024 --> Sep 2025
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Multiple Choroidal Neovascularizations in Choroidal Osteoma Treated with Anti-VEGF Injections: A 6-Year Follow-Up Case Report. (Pubmed Central) - Mar 5, 2024
Multiple CNVs may appear simultaneously at different locations in one osteoma and prompt treatment with intravitreal anti-VEGF may be a good option to control the progression and recurrence of these CNVs. Long-term follow-up and multimodal imaging are vital in the management of CO-associated CNV.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Topical Ophthalmic Liposomes Dual-Modified with Penetratin and Hyaluronic Acid for the Noninvasive Treatment of Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Mar 3, 2024
In a laser-induced choroidal neovascularization (CNV) mouse model, PenHA-Lip/Conb eye drops three times daily for seven days inhibited CNV formation and progression without any significant tissue toxicity and achieved an equivalent effect to a single intravitreal conbercept injection. PenHA-Lip efficiently and safely delivered conbercept to the posterior eye segment and may be a promising noninvasive therapeutic option for nAMD.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Retrospective data, Journal: Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization. (Pubmed Central) - Feb 24, 2024
Intravitreal injection of conbercept is beneficial to eyes with ICNV, inducing the recovery of macular structure and function and improving BCVA, while not damaging the neuroretina. Intravitreal conbercept is safe and effective for the treatment of ICNV.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Intravitreal injection of conbercept for diabetic macular edema complicated with diabetic nephropathy. (Pubmed Central) - Feb 19, 2024
Intravitreal conbercept is safe and effective for the treatment of ICNV. Conbercept has a significant effect in short-term treatment of DME patients with or without DN, and can significantly ameliorate BCVA, CMT and the number of HF, treatment efficacy of DME patients without DN is better than that of DME patients with DN.
- || Retrospective data, Review, Journal: Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. (Pubmed Central) - Jan 30, 2024
We found no evidence that any drug increases all-cause mortality compared to control, but estimates were very imprecise. Evidence from RCTs may not apply to real-world practice, where people in need of antiangiogenic treatment are often under-treated, and the individuals exposed to these drugs may be less healthy than trial participants.
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
Preclinical, Journal: Topical Application of Cell-Penetrating Peptide Modified Anti-VEGF Drug Alleviated Choroidal Neovascularization in Mice. (Pubmed Central) - Jan 12, 2024
Effectively delivering the anti-VEGF drugs to the target area in a non-invasive manner, suppressing the progression of laser-induced CNV. This offers a novel approach for the treatment of wet AMD.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal, Surgery: Scleral incision and open fluid surgery combined with vitreous cavity injection (conbercept) for the treatment of Coats: A case report. (Pubmed Central) - Dec 23, 2023
This offers a novel approach for the treatment of wet AMD. No abstract available
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Biomarker, Journal: Optical coherence tomography angiography for macular microvessels in ischemic branch retinal vein occlusion treated with conbercept: predictive factors for the prognosis. (Pubmed Central) - Dec 19, 2023
Using OCTA to observe macular ischemia and quantify parameters can better predict the final visual prognosis of patients before treatment. The changes in FAZ parameters may influence the visual prognosis and injection times.
- | Retrospective data, Journal: Different approaches for treating myopic choroidal neovascularization: a network Meta-analysis. (Pubmed Central) - Dec 19, 2023
Anti-VEGF has the best effect on long-term vision improvement in mCNV patients, using IVB or IVR alone to treat mCNV may be better than IVB or IVR combined with PDT. There is no significant difference in the improvement of visual acuity, macular edema, and CRA in mCNV patients treated with any different anti-VEGF drugs.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New trial: Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema (EUDRACT) - Dec 5, 2023
P=N/A, N=150, Not yet recruiting, Sponsor: Department of Ophthalmology, Affiliated Hospital of Beihua University; Department of Ophthalmology, Affiliated Hospital of Beihua University
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New P4 trial: A study to evaluate the long-term safety of conbercept ophthalmic injection in the treatment of neovascular age-related macular degeneration (nAMD) (EUDRACT) - Dec 5, 2023
P4, N=500, Completed, Sponsor: Peking University People's Hospital; Chengdu Kanghong Biotechnology Co., LTD
- || Lumitin (conbercept) / Chengdu Kanghong Pharma
Review: Anti-vascular endothelial growth factor therapy regimens for polypoidal choroidal vasculopathy: a systematic review. (Pubmed Central) - Nov 27, 2023
This limited evidence suggests that current treatment regimens are similarly efficacious, though T&E aflibercept achieved superior outcomes when compared to bimonthly dosing or PRN in some individual studies. Further trials are needed to confirm or refute these findings.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Review, Journal: Comparative efficacy of aflibercept and ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis. (Pubmed Central) - Nov 26, 2023
Further trials are needed to confirm or refute these findings. IVA appears to be superior to IVR in improvement of BCVA, height decrease of PED and regression of PED with less injections in nAMD with PED.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Hemorrhagic retinal arterial macroaneurysm combined with branch retinal artery occlusion treated with intravitreal conbercept injection: A case report. (Pubmed Central) - Nov 4, 2023
IVA appears to be superior to IVR in improvement of BCVA, height decrease of PED and regression of PED with less injections in nAMD with PED. Administration of conbercept injection might be an effective treatment for complex RAM with BRAO.
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
Journal: Early effects of intravitreal anti-VEGF agents on cornea and visual acuity in patients with diabetic retinopathy. (Pubmed Central) - Oct 22, 2023
Intravitreal administration of anti-VEGF agents could cause a small but significant greater increase in CCT in PDR than in NPDR eyes in the early period. In patients with DR, no significant difference was found between conbercept and ranibizumab in the early effects on the visual acuity nor in the cornea.
- || Avastin (bevacizumab) / Roche, Lumitin (conbercept) / Chengdu Kanghong Pharma
Retrospective data, Review, Journal: Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials. (Pubmed Central) - Oct 10, 2023
In patients with DR, no significant difference was found between conbercept and ranibizumab in the early effects on the visual acuity nor in the cornea. Bevacizumab (0.625
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-na (clinicaltrials.gov) - Oct 5, 2023
P=N/A, N=102, Not yet recruiting, Sponsor: Tianjin Medical University Eye Hospital
Bevacizumab (0.625 N=52 --> 102 | Trial completion date: Aug 2025 --> Nov 2025 | Initiation date: Aug 2023 --> Nov 2023 | Trial primary completion date: Aug 2024 --> Nov 2024